Objective: After discovering the association between the HLA-B*15:02 allele and carbamazepine-related severe cutaneous adverse reactions (SCARs), particularly in Southeastern Asian populations, clinical strategies to prevent carbamazepine-related SCARs have changed. We aimed to investigate 10-year trends in carbamazepine use and carbamazepine-related SCARs and to examine the patterns and determinants of HLA-B*15:02 screening in Taiwan. Methods: A nationwide study was performed using Taiwan's National Health Insurance Research Database. In the first part of the study, new users of carbamazepine were included, and those who experienced SCAR-related admissions were further identified. In the second part of the study, recipients of HLA-B*15:02 screening (reimbursed by Taiwan's National Health Insurance since June 2010) were included and multivariate logistic regression was used to explore factors associated with the use of screening. Results: The numbers of new users of carbamazepine and SCAR cases decreased remarkably during the 10-year period (−82.6% and −87.1%, respectively), and the incidence rates of SCARs showed a downward trend after 2011. The screening rate of the HLA-B*15:02 allele increased to 24.9% in 2014. Neurologists (odds ratio 12.33, 95% confidence interval 9.30-16.35), psychiatrists (9.97, 7.31-13.61), and neurosurgeons (3.23, 2.42-4.32) were more likely to perform screening tests than other specialties were. Physicians practicing in medical centers (6.00, 5.51-6.54) were more likely to perform screening tests than those practicing in other hospitals, whereas the screening rates in clinics remained at 0.0% throughout the study period. Significance: In recent years, the number of carbamazepine-related SCAR cases has decreased substantially in Taiwan. However, only one-fourth of new users of carbamazepine received HLA-B*15:02 screening, and there were considerable disparities in the screening rates across different physician groups. Policymakers should consider solutions to barriers to implementing screening tests in clinical practice and should not neglect the value of other safety communications and regulations to complement the limitations of pharmacogenomic testing.
| INTRODUCTION
Carbamazepine is used widely in the treatment of epilepsy, bipolar disorder, and neuropathic pain, 1 but it is also notorious for its potential risk of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reactions with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGP). [2] [3] [4] SCARs are associated with a high mortality rate (up to 40%) and carry a nonnegligible risk of long-term sequelae, such as dystrophic scars and synechiae, visual loss, and end-organ failure, which may critically affect patient quality of life. 2, [5] [6] [7] Epidemiology data have shown that the incidence rates of carbamazepine-related SCARs were much higher in Southeast Asian countries than in the United States (eg, SJS: 59 cases per 100 000 new users per year in Taiwan vs 2 cases per 100 000 new users per year in the United States). 8 Over the past decade, clinical strategies to prevent SCARs among patients initiating carbamazepine use have changed dramatically after the association between the human leukocyte antigen (HLA)-B*15:02 allele and carbamazepinerelated SJS/TEN was revealed. This genetic association was first found in Han Chinese 9, 10 and was further confirmed in many Southeastern Asian countries, [11] [12] [13] [14] with overall high sensitivity (odds ratio [OR] 0.96, 95% confidence interval [CI] 0.69-0.99) and high specificity (0.88, 95% CI 0.82-0.93). 15 Because the frequency of the HLA-B*15:02 allele was found to vary among different ethnic groups (6%-10% in Han Chinese, 5%-27% in Southeastern Asian countries, and 0.1%-2% in Caucasians), 16 in December 2007, the US Food and Drug Administration (FDA) recommended genetic screening before commencing carbamazepine among patients with ancestry from areas where HLA-B*15:02 allele is present. 17 Similar recommendations were subsequently made by regulatory bodies in the United Kingdom, Hong Kong, Singapore, Thailand, and India. 16 In Taiwan, in September 2008, the Taiwan Food and Drug Administration (TFDA) also added a new warning to the drug label of carbamazepine regarding the genetic association, and the screening test for the HLA-B*15:02 allele was reimbursed by Taiwan's National Health Insurance (NHI) in June 2010. 16 Despite numerous safety communications available worldwide, whether these recommendations translate well into clinical practice is questioned. 18 A clinical trial conducted in Taiwan showed that avoiding carbamazepine use in patients carrying the HLA-B*1502 allele was associated with a decreased incidence of carbamazepinerelated SJS/TEN compared to the historical incidence. 19 However, real-world data regarding the utilization and impact of HLA-B*15:02 screening are scarce. To the best of our knowledge, only one study conducted in Hong Kong assessed the impact of implementing screening tests in real-world practice, and the study highlighted the unintended effects after the HLA-B*15:02 screening policy began. 20 According to their findings, apart from the positive effects (postpolicy incidence rates of carbamazepine-related SJS/TEN reduced to 0%), negative effects also occurred (postpolicy incidence rates of phenytoin-related SJS/TEN increased) possibly due to channeling of high-risk patients from carbamazepine to phenytoin, another aromatic antiepileptic drug (AED) also carrying the risk of SCARs. Accordingly, although the HLA-B*15:02 screening test seems to hold promise for preventing carbamazepine-related SCARs, it is essential to examine both its intended and unintended impacts in real-world settings to guide future safety-related policies for carbamazepine. We thus conducted this nationwide study using Taiwan's National Health Insurance Research Database (NHIRD), which includes 99% of Taiwan's population of more than 23 million and therefore allows the detection of rare events, such as SCARs. 21 In the first part of our study, we aimed to investigate the 10-year trends of carbamazepine use and the incidence of SCARs among new users of carbamazepine in Taiwan; in the second part of our study, we aimed to examine the trends of the HLA-B*15:02 screening rate and the determinants of HLA-B*15:02 screening in Taiwan.
Key Points
• In the past 10 years, new users of carbamazepine in Taiwan have substantially decreased 21 Comprehensive data, including patient demographics, diagnosis, prescriptions, and health care utilization, are well documented in the database. 22 Data from the NHIRD have been used extensively to conduct realworld studies assessing the population-based utilization pattern, effectiveness, and safety of drugs. [23] [24] [25] Claims data from 2000 to 2015 were extracted for this analysis. This study was approved by the institutional review board of the National Taiwan University Hospital (201603028W), and informed consent was waived because the identifying information in the NHIRD is encrypted to ensure privacy.
| Study cohorts
In the first part of our study, new users of carbamazepine were included as the study cohort to evaluate trends in carbamazepine-related SCARs. Patients who started carbamazepine between January 2005 and December 2014 and who had not received carbamazepine prescriptions in the preceding 5 years were defined as new users, and the date of the first carbamazepine prescription was defined as the index prescription date. New users with preexisting cutaneous adverse reaction-related diagnosis records in the 3 months before the index prescription date were further excluded to identify incident cases of SCAR ( Figure S1 ). In the second part of our study, recipients and nonrecipients of HLA-B*15:02 screening tests were identified. Patients receiving HLA-B*15:02 screening tests between June 2010 and December 2014 who had not received carbamazepine prescriptions in the preceding 5 years were defined as screening recipients, and the date of the screening was defined as the index screening date. New users of carbamazepine who received their first prescriptions between June 2010 and December 2014 but had not received HLA-B*15:02 screening tests before the index prescription date were identified as screening nonrecipients. Patients who received HLA-B*15:02 screening tests or first carbamazepine prescriptions during hospital admissions were further excluded because the temporal sequence between HLA-B*15:02 screening tests and carbamazepine prescriptions during the hospitalization were difficult to be ascertained in the NHIRD ( Figure S2 ).
| Carbamazepine-related severe cutaneous adverse reactions (SCARs)
Incident cases of SCARs were identified using the The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 693.0, 695.1, 695.89, and 695.9. The accuracy of these diagnosis codes has been validated using hospital system-based medical records in a previous study. 23 To increase the validity, only new users of carbamazepine admitted with a diagnosis of SCARs and without further prescription records of carbamazepine within 6 months after the admission were accounted as having a SCAR. We adopted the as-treated (AT) approach for the primary analysis of the incidence of SCARs among new users of carbamazepine, and each patient was followed from the index prescription date until the earliest occurrence of the following: SCARs, discontinued use of carbamazepine for more than 1 month, death, and 3 months after the index prescription date. We further conducted a series of prespecified sensitivity analyses to test the robustness of our results. First, to address the potential impact of the duration of the follow-up period on the incidence of SCARs, we adopted the intention-to-treat (ITT) approach (analysis a) and the as-treated approach (analysis b) by defining the discontinued use of carbamazepine as having a gap of greater than 7 days. Second, to avoid confounding by previous exposure to other medications, analysis c restricted the study cohort to patients who had not received any prescriptions of antiepileptic drugs in the past 5 years, and analysis d excluded SCAR cases that were concomitantly exposed to ''highly suspected'' drugs (Table S1 provides the list of highly suspected drugs in the prior literature 2 ).
Finally, different definitions of SCARs have been used in previous studies 19, 26 ; therefore, analysis e identified SCAR cases using only ICD-9-CM codes 695.1, and analysis f included only SCAR cases admitted to the dermatology department.
| HLA-B*15:02 screening and postscreening antiepileptic drug prescriptions
The receipt of HLA-B*15:02 screening tests was extracted from claims data using a specific payment code (12196B) in Taiwan's NHI system. The quarterly screening rates of HLA-B*15:02 were calculated using the following formula: screening rate = (number of screening recipients)/(number of screening recipients + number of screening non-recipients). In addition, newly used AEDs after screening were assessed and the newly used AEDs were defined as those that were not prescribed in the last prescriptions before screening but only after screening. accreditation level is medical center, followed by regional hospital, district hospital, and clinic. Medical institutions with higher accreditation levels have more inpatient beds and specialties (eg, medical centers have >500 beds and >25 specialties; Regional Hospitals have ≥250 beds and ≥7 specialties; district hospitals have <250 beds and <7 specialties; and clinics provide only outpatient services) are more capable of providing critical care services, and are more involved in teaching and researches. [29] [30] [31] The daily dose of carbamazepine prescriptions was calculated using defined daily dose (DDD); the DDD of carbamazepine is 1000 mg.
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Multivariate logistic regression models were conducted to explore the potential factors associated with the adoption of HLA-B*15:02 screening tests. The associations are presented as ORs with 95% CIs. All the analyses were performed using SAS version 9.4 (SAS Institute Inc.). A 2-sided P value was used with P < 0.05 considered statistically significant.
| RESULTS

| Trends in new users of carbamazepine and patient characteristics
There were 424 920 new users of carbamazepine between 2005 and 2014 ( Figure S1 ). After excluding patients of unknown sex and age and patients with preexisting SCARs, 419 900 new users of carbamazepine were included in the study. The number of new users decreased by 82.6% during the 10-year period, from 76 140 in 2005 to 13 243 in 2014 ( Table 1 ). The distribution of patient characteristics changed slightly over time, with an increasing proportion of female and older patients. In early years, most of the new users received their first carbamazepine prescriptions from neurologists, whereas in recent years, most new users received their first carbamazepine prescriptions from internal medicine physicians. The proportion of new users who received their first carbamazepine prescriptions from clinics increased 1.7-fold during the study period, resulting in nearly 60% of first carbamazepine prescriptions from clinics in 2014. In more than 90% of new users of carbamazepine, the daily dose of the first prescriptions was less than 0.5 DDD (500 mg). The most common indication for new carbamazepine prescriptions was trigeminal neuralgia, but more than 80% of prescriptions of carbamazepine were off-label. . Similar trends were observed in most of the sensitivity analyses, but very low incidence rates were observed when analyses was restricted to SCAR cases admitted to a dermatology department ( Figure S3 ).
| Trends in SCARs among new users of carbamazepine
| Trends in HLA-B*15:02 screening rates and factors associated with screening
There were 8983 recipients and 74 095 nonrecipients of HLA-B*15:02 screening included in the study ( Figure S2 ). After HLA-B*15:02 screening tests were reimbursed by NHI in June 2010, the overall screening rates increased from 1.4% to 24.9% after 4.5 years (Figure 2A ). The screening rates were different across age groups. A more pronounced increase was found in patients aged ≤20 years (63.0% at the end of study period) and aged 21-40 years (33.1%), whereas similar screening rates were found in patients aged >40 years (19.7%-23.3%) ( Figure 2B ). Compared to off-label use (14.2%), patients with a diagnosis of epilepsy (64.0%), trigeminal neuralgia (52.4%), or bipolar disorders (41.4%) had higher screening rates ( Figure 2C ). There were also notable differences in analyses stratified by provider characteristics. Neurologists, neurosurgeons, and psychiatrists showed a more pronounced increase of screening rates, whereas low screening rates (<10%) throughout the study period were observed among physicians in family medicine, internal medicine, | 2331 otolaryngology, and orthopedics ( Figure 2D ). Medical centers took only 1.5 years to reach a 50% screening rate, whereas regional hospitals took 4.5 years. Furthermore, after 4.5 years, district hospitals reached only a 22.5% screening rate, and the screening rates in clinics remained 0.0% throughout the entire study period ( Figure 2E ). 
| DISCUSSION
In this nationwide study investigating the 10-year trends in new users of carbamazepine and carbamazepine-related SCARs, we found that new users of carbamazepine in Taiwan substantially decreased over time, and there was a simultaneous decrease in the number of carbamazepinerelated SCAR cases. Moreover, this study contributes to the emerging literature on pharmacogenetics testing by evaluating the trends and determinants of HLA-B*15:02 screening. At the end of our study, only 25% of new users were screened before receiving their first prescriptions of carbamazepine, and there were considerable disparities in screening rates across different patient and physician groups. The significant decrease of new users of carbamazepine over the past 10 years may be associated with the availability of newer AEDs. A previous study has reported a large shift from old AEDs toward new AEDs in both epilepsy and nonepilepsy disorders. 33 Similar results were also found in Taiwan. As shown in Figure S5 , new users of most of the old AEDs (carbamazepine, phenytoin, and phenobarbital) declined over time, and there was an increase in new users of new AEDs. In addition, apart from regulations regarding the genetic associations in September 2008 and the reimbursement of HLA-B*15:02 screening tests in June 2010, the TFDA also issued several safety-related regulations for carbamazepine during the study period, including indication restrictions, labeling revisions, the reinforcement of labeling on medication containers, and Risk Evaluation and Mitigation Strategies (REMS) (Figure S7) , which may all have contributed to the decline in new users of carbamazepine. Consequently, this great reduction in new users of carbamazepine resulted in a remarkable decrease of the cases of carbamazepine-related SCARs.
Although new users of carbamazepine decreased dramatically over time, concerns have been raised due to very extensive off-label use of carbamazepine found in our study, which has also been pointed out in a previous study in Taiwan. 34 There may be several explanations for this phenomenon. First, the regulator-approved indications for carbamazepine in Taiwan are epilepsy, trigeminal neuralgia, bipolar disorder, and diabetes insipidus, but there are many other indications supported by literature, such as peripheral neuropathy and schizophrenia. 34, 35 Second, the proportion of off-label use was much lower when we analyzed not only the first prescriptions (eg, 91% in 2005 and 80% in 2014) but all the prescriptions of carbamazepine (eg, 56% in 2005 and 38% in 2014), which indicated that physicians may be unable to make definitive diagnosis upon the first carbamazepine prescriptions. For example, according to the definition of the International League Against Epilepsy (ILAE), epilepsy can be diagnosed when at least 2 unprovoked seizures occur >24 hours apart. 36 Third, since we investigated the treatment indications based on records of diagnoses from the NHIRD, in which up to 3 diagnoses are allowed for each outpatient claim, we may overestimate the proportion of off-label use, especially among patients with multiple comorbidities. Nevertheless, the TFDA has emphasized the importance of restricting off-label use through several regulations in the past 10 years ( Figure S7 ) to improve rational use of carbamazepine, and the prevalence of off-label use of carbamazepine declined over time. A downward trend of the incidence rates of carbamazepine-related SCARs was also found after 2011, which may reveal the positive intended effects of the implementation of HLA-B*15:02 screening. This finding was consistent with the observation in Hong Kong where the incidence of carbamazepine-related SJS/TEN decreased from 0.24% to 0% after the genetic screening policy began. 20 However, given the very low incidence rate of SCARs, small changes of the number of cases may cause large fluctuations in incidence rates. Continuous monitoring of the incidence rates of carbamazepine-related SCARs is still warranted to see whether the decline occurred coincidentally or was sustained after the implementation of HLA-B*15:02 screening.
Despite the positive effects of HLA-B*15:02 screening, challenges in the clinical implementation of pharmacogenomics still remain. A previous study classified common barriers for pharmacogenomic testing into 5 categories: reimbursement, ELSI (ethical, legal, and social issue), and regulation, education, scientific, and information technology. 37 There was no reimbursement barrier in Taiwan after the HLA-B*15:02 screening test was reimbursed by the NHI, a nationwide, mandatory enrollment and single-payer health system. However, our study revealed that the overall screening rates only achieved 25% after 4.5 years, and the screening rates varied widely by different physician subgroups. These findings noted that, on top of providing universal access to the HLA-B*15:02 screening tests, efforts should be made to address barriers other than economic issues. Education barriers have been suggested to be the most influential barriers for implementing pharmacogenomic testing into daily routine practice. 37 As shown in our study, specialized physicians, particularly neurologists, psychiatrists, and neurosurgeons, were more likely to perform HLA-B*15:02 screening tests than physicians in family medicine and internal medicine. In contrast to specialized physicians who have more experience with prescribing carbamazepine, physicians in family medicine and internal medicine may lack awareness of the risk and the seriousness of carbamazepine-related SCARs, as well as the knowledge to apply HLA-B*15:02 screening tests for preventing SCARs. Similarly, higher screening rates have been observed in physicians practicing in medical centers. Physicians practicing in hospitals with lower accreditation levels may have fewer opportunities to receive updated training on pharmacogenomics and be less likely to have an electronic health record (EHR) system with a clinical decision support system (CDS) 38, 39 to alert them to perform the tests or support them in making decisions based on test results. Because drug safety communication letters including information about HLA-B*15:02 screening tests have been delivered to physicians and pharmacists through the Risk Evaluation and Mitigation Strategies (or REMS) issued by the TFDA in September 2011 ( Figure S7 ), policymakers may consider other specific education strategies, such as seminars held in hospitals with lower accreditation levels or lectures incorporated into conferences offered by targeted professional organizations (eg, associations of family medicine and associations of internal medicine).
Once physicians are aware of the importance of pharmacogenetic testing and decide to perform the tests, scientific barriers, such as the availability and turnaround time of the tests, will be the next barriers. 37 In our study, concerns were raised with respect to the 0.0% HLA-B*15:02 screening rates in clinics throughout the study period, and this phenomenon may be due mainly to the lack of certificated laboratories to perform pharmacogenetic testing in clinics. Moreover, even hospitals that are able to perform the screening tests still face the problem of a relatively long waiting time. For example, according to the laboratory protocols in several medical centers in Taiwan, the HLA-B*15:02 tests were only performed twice a week and the waiting time needed for reports was approximately 7 days. These technical issues highlight the practical obstacles of pharmacogenetic testing and inform policymakers on both the importance of finding solutions to these barriers and the necessity of continuing traditional safety communication, such as education on detecting the early signs and symptoms of SCARs, especially under clinical circumstances in which performing the HLA-B*15:02 test before prescribing carbamazepine is not feasible. As expected, carbamazepine was the most frequently prescribed AEDs after HLA-B*15:02 screening, but the prescribing rate was still relatively low. According to a previous study in Taiwan, the carrier rate of the HLA-B*15:02 allele was 7.7%, 9 but we found that only 31.2%
of screening recipients received carbamazepine prescriptions. The time required for test results may partially explain this discordance. It is possible that when patients require immediate treatment to relieve their symptoms, physicians choose to prescribe alternative drugs first while waiting for the results of pharmacogenetic testing. They may maintain the same drug therapy for well-controlled patients without changing to carbamazepine even after getting a negative test results. This could be due to concerns that switching from one drug to another may expose patients to the risk of breakthrough seizures. The second frequently prescribed AED was oxcarbazepine, which is an analog of carbamazepine that may be first considered as an alternative to carbamazepine by the physicians. Other AEDs may be prescribed more frequently because they have more indications (eg, valproate for bipolar disease and gabapentin for neuralgia) or they were not restricted for specific patient populations (eg, some reimbursement constraints were imposed by the National Health Insurance Administration of Taiwan on topiramate, levetiracetam, lamotrigine, gabapentin, pregabalin, and vigabatrin: that these AEDs could be prescribed only as second-line or add-on therapy for treatment of epilepsy 40 ). It is worth noting that 47.2% of recipients of HLA-B*15:02 screening were not newly prescribed with any AEDs in our study. The previous study in Hong Kong also found that 44.5% of recipients of the screening were not subsequently prescribed with any AEDs. 20 One reason is that some of the HLA-B*15:02 screening tests may not be point-of-care tests (ie, testing performed at the time a new medication is needed) but preemptive tests (ie, testing completed prior to a specific need). 41 Another reason is that our study focused mainly on AEDs, but carbamazepine has indications other LIN ET AL.
than epilepsy that can be treated using other drugs (eg, lithium or antipsychotics for bipolar disorder). Furthermore, there were concerns regarding the unintended effects of the implementation of HLA-B*15:02 screening in clinical practice. The aforementioned study in Hong Kong reported the increase of phenytoin-related SJS/ TEN after the genetic screening policy began, which may be due to the physicians' decisions to prescribe phenytoin as alternative AEDs for HLA-B*15:02-positive patients. 20 Prior studies have shown that not only carbamazepine but also other aromatic AEDs (including phenytoin, phenobarbital, oxcarbazepine, and lamotrigine) carry the risk of SCARs, 8, 27 and cross-sensitivity to other aromatic AEDs have been observed in patients who developed carbamazepine-related SCARs. 42 Notably, accumulating evidence has found that the HLA-B*15:02 allele was also associated with phenytoin-and oxcarbazepine-related SCARs. 11, 26, 43 Therefore, to evaluate the possibility of Newly prescribed AEDs were defined as those that were not prescribed in the last prescriptions before screening but only after screening.
unintended effects, we studied AEDs newly prescribed after genetic testing and further evaluated the trends in other AED-related SCARs using the same methods for carbamazepine-related SCARs ( Figure S6 ). We found that after HLA-B*15:02 screening, the most frequently prescribed AEDs other than carbamazepine were oxcarbazepine (15.2%), clonazepam (10.7%), valproate (7.1%), and gabapentin (6.3%), but there were no upward trends of SCARs found in new users of these AEDs. However, we did find an increased incidence of SCARs in new users of phenytoin and phenobarbital after 2012, but this is less likely related to the implementation of HLA-B*15:02 screening policy because there were fewer patients receiving phenytoin and phenobarbital after genetic testing (3.8% and 0.5%, respectively). Nevertheless, future education and policy about HLA-B*15:02 screening should also emphasize the importance of the appropriate selection of alternative AEDs after screening tests.
Findings from this study could provide insights for future drug safety communication strategies and the delivery of pharmacogenetic testing services in clinical practice. However, there were also several limitations inherent to studies using the claims database that need to be addressed. First, the incidence of SCARs may be under-or overestimated because we relied on diagnosis codes to identify cases of SCARs. To improve the reliability of our estimation, we used previously validated ICD-9-CM codes and restricted to cases admitted to the hospital. In addition, we conducted a series of sensitivity analyses, and multiple analyses have shown similar trends of incidence. The analysis of time latency between the initiation of carbamazepine use and onset of SCARs ( Figure S4 ) also yielded results consistent with those of the EuroSCAR study. 4 Second, the test results of HLA-B*15:02 screening were not available in the NHIRD, so we could not assess whether physicians prescribed carbamazepine based on test results or assess AEDs newly prescribed for HLA-B*15:02-positive patients. Third, we could not differentiate whether the HLA-B*15:02 screenings were point-of-care tests or preemptive tests, 41 and these different approaches may influence the prescribing rate of carbamazepine or other AEDs after the screening tests. Fourth, it would be of interest to test whether there was a statistically significant trend change in incidence rate of carbamazepine-related SCARs before and after the implementation of HLA-B*15:02 screening using interrupted time series analysis with segmented regression. 44 However, because there were only 5 data points before the implementation of screening (2005) (2006) (2007) (2008) (2009) ) and 4 data points after (2011-2014), our data did not fulfill the criteria for constructing the segmented regression models (ie, 12 data points in each segment). 44 Finally, given the unique national health system and country-specific safety regulations of carbamazepine in Taiwan, the results from our study may not be directly applicable to other countries.
| CONCLUSIONS
In recent years, new users and SCAR cases of carbamazepine have substantially decreased in Taiwan. However, only one-fourth of new users were screened for the HLA-B*15:02 allele before receiving their first prescriptions at the end of the study period, and there were considerable disparities in the screening rates across medical specialties and hospital accreditation levels. Despite the significant advancement in pharmacogenomic testing for preventing carbamazepine-related SCARs, policymakers should consider solutions to barriers to implementing screening tests in clinical practice and should not neglect the value of other drug safety communications, education, and regulations to complement the limitations of pharmacogenomic testing.
